CD8A and atherosclerosis: Since the clinical trial of avasimibe in atherosclerosis in the late 1990s, there has been a renewed interest in avasimibe as a potential anticancer agent as a result of data showing that avasimibe can potentiate the anti-tumor response of CD8+T cells [22].